A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.

@article{Britten2001API,
  title={A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.},
  author={Carolyn D. Britten and Eric K. Rowinsky and S Soignet and Amita Patnaik and Shimou Yao and Philippe Deutsch and Yongjae Lee and Robert B. Lobell and Kathryn E Mazina and Heather J McCreery and S Pezzuli and David R. Spriggs},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2001},
  volume={7 12},
  pages={
          3894-903
        }
}
This Phase I study was performed to assess the feasibility of administering L-778,123, a peptidomimetic farnesyl protein transferase (FPTase) inhibitor, as a continuous i.v. infusion for 7 days every 3 weeks and to determine the recommended dose for subsequent disease-directed trials. This study also sought to characterize the pharmacological behavior of L-778,123 and to determine whether the desired biological effect, inhibition of protein farnesylation, could be detected and assessed during… CONTINUE READING
Highly Cited
This paper has 47 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

Genetics of melanoma

Front. Gene. • 2012
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Phase I trial of the farnesyl protein transferase inhibitor L-778,123 on a 14- or 28-day dosing schedule

E. Rubin, J. L. Abbruzzese, +8 authors C. Fuchs
Proc. Annu. Meet. Am. Soc. Clin. Oncol., • 2000
View 4 Excerpts
Highly Influenced

Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2001
View 2 Excerpts

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2000
View 2 Excerpts

Phase I and pharmacologic study with the novel farnesyltransferase inhibitor R115777

J. H. Schellens, G. de Klerk, +7 authors W. W. ten Bokkel Huinink
Proc. Annu. Meet. Am. Soc. Clin. Oncol., • 2000
View 2 Excerpts